Deletion polymorphism in the angiotensin converting enzyme (ACE) gene: Significance for progression of ACE-inhibition treated diabetic nephropathy;Betydningen af deletionspolymorfi i ACE-genet for progression af ACE- haemmerbehandlet diabetisk nyresygdom

Ugeskrift for Laeger

Volumn 160, Issue 34, 1998, Pages 4886-4889

  Tarnow, Lise ^a   Parving, Hans Henrik ^b   Jacobsen, Peter ^b   Rossing, Peter ^b   Lecerf, Laure ^b   Poirier, Odette ^b   Combien, Francois ^b  

^a STENO DIABETES CENTER   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALLELE; ARTICLE; BLOOD PRESSURE; DIABETIC NEPHROPATHY; GENE DELETION; GENE INSERTION; GLOMERULUS FILTRATION RATE; HOMOZYGOSITY; PROTEINURIA;

ADULT; ALLELES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CHROMOSOME DELETION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; MALE; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 0032541393     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72. 375-80.
2. Parving H-H, Østerby R, Andersen PW, Hsueh WA. Diabetic nephropathy. I: Brenner BM, ed. The kidney. 5th ed. Philadelphia: Saunders, 1996: 1864-92.
3. Erdos EG. Angiotensin I-converting enzyme and the changes in our concepts through the years. Hypertension 1990; 16: 363-70.
4. Marre M, Chatellier G, Leblanc H, Guyenne T-T, Ménard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297: 1092-5.
5. Mathiesen ER, Hommel E, Giese J, Parving H-H. Efficacy of captopril in postponing nephropathy in normotensive diabetic patients with microalbuminuria BMJ 1991; 303: 81-7.
6. Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988; 297: 1086-91.
7. Lewis E, Hunsicker L, Bain R, Rhode R. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
8. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R et al. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96: 2162-9.
9. Harden PN, Geddes C, Rowe PA, Mcllroy JH, Boulton-Jones M, Rogers S et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345: 1540-2.
10. Tamow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995; 44: 489-94.
11. Bröchner-Mortensen J, Rödbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976; 36: 35-45.
12. Bröchner-Mortensen J. Current status on assessment and measurement of glomerular filtration rate. Clin Physiol 1985; 5: 1-17.
13. Levey AS, Gassman J, Hall PM, Walker WG. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. J Am Soc Nephrol 1991; 1: 1087-94.
14. Van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ et al. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996; 347: 94-5.
15. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 1981; 20: 457-61.
16. Parving H-H, Rossing P, Hommel E, Smidt UM. Angiotensin converting enzyme inhibition in diabetic nephropathy: ten years experience. Am J Kidney Dis 1995; 26: 99-107.
17. Parving H-H, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175-9.
18. Rossing P, Hommel E, Smidt UM, Parving H-H. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993; 42: 715-9.
19. Breyer JA, McGiil JB, Nahman NS. Predictors of the rate of progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy [abstract]. J Am Soc Nephrol 1993; 4: 301.
20. Ueda S, Elliott HL, Morton JJ, Connel JMC. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotens in-converting enzyme. Hypertension 1995, 25: 1266-9.